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Abstract
Ionizing radiation (IR) is used frequently in the management of multiple tumor types, including both
organ-conﬁned and locally advanced prostate cancer (PCa). Enhancing tumor radiosensitivity
could both reduce the amount of radiation required for deﬁnitive treatment and improve clinical
outcome. Androgen suppression therapy improves clinical outcomes when combined with
radiation therapy but is associated with signiﬁcant acute and chronic toxicities; hence, there is a
clear need for alternative means to increase the therapeutic window of radiotherapy. Herein, it is
demonstrated that the mammalian target of rapamycin (mTOR) inhibitors rapamycin (sirolimus)
and temsirolimus limit both hormone therapy (HT)-sensitive and castration-resistant PCa (CRPC)
cell proliferation as single agents and have a profound radiosensitization effect when used in
combination with IR. Importantly, the observed radiosensitization was inﬂuenced by the treatment
schedule, in which adjuvant administration of mTOR inhibitors was most effective in limiting PCa
cell population doubling. This schedule-dependent inﬂuence on in vitro treatment outcome was
determined to be the result of relative effects on the cell cycle kinetics. Finally, adjuvant
administration of either mTOR inhibitor tested after IR signiﬁcantly decreased clonogenic cell
survival of both HT-sensitive and CRPC cells compared with IR alone. Taken together, these data
demonstrate that inhibition of mTOR confers a radiosensitization phenotype that is dependent on
relative cell cycle kinetics and provide a foundation for clinical assessment.
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Introduction
Prostate cancer (PCa) is the most frequently diagnosed
non-cutaneous malignancy and the second leading
cause of death due to cancer in men in the United States
(Jemal et al. 2010). Treatment options for localized
disease include watchful waiting, surgery, and radio-
therapy (RT; Klein et al. 2009). In the context of
deﬁnitive treatment, adjuvant therapy after radical
prostatectomy, and in some cases metastatic disease,
RT is becoming of increasing signiﬁcance for success-
ful management of PCa (Kwok & Yovino 2010).
Androgensandthecognatereceptor(androgenreceptor
(AR)) have a well-described function in all stages of PCa.
Ifdisseminatedatthetimeofdiagnosis,ﬁrst-linetherapyis
targetedagainsttheARsignalingaxis.SuppressionofAR
activity is achieved by using GnRH agonists that induce
ligand depletion (chemical castration) and is sometimes
used in combination with direct AR antagonists (such
as bicalutamide; Klotz 2006, Loblaw et al. 2007, Taplin
2007, Chen et al. 2008, Knudsen & Scher 2009). For
locally advanced or high-risk disease, RT is frequently
used, thus underscoring the need to delineate the impact
of combination therapy. AR-directed therapeutics is
initially effective due to the dependence of this tumor
typeonARsignaling;however,afteramediantimeof2–3
years, tumors recur and are deemed ‘castration resistant’
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is highly attributed to inappropriate resurgence of
AR activity, which occurs despite the absence
of circulating serum androgens and administration of
direct AR antagonists (Knudsen & Scher 2009, Yuan &
Balk 2009). Strikingly, few therapeutic options have
shown efﬁcacy against this stage of the disease, and
amajorgoalofcurrenttranslationalresearchistodevelop
means for preventing or delaying progression to CRPC.
One means by which PCa cells bypass AR-directed
therapeutics involves upregulation of rapamycin (Rapa)-
sensitive signaling (Mousses et al.2 0 0 1 ), and that
combining mammalian target of rapamycin (mTOR)
inhibition with AR-directed therapies prolongs hormone
sensitivity in xenograft models of PCa (Schayowitz
et al.2 0 1 0 ). Moreover, AR is known to promote mTOR
activity (Xu et al. 2006b), thus suggesting that combining
mTOR- and AR-directed therapeutics may cooperate to
improve cellular and clinical responses to therapy.
Given the poor outcomes associated with resurgent
AR activity and CRPC development, it is imperative to
develop new means for enhancing therapeutic efﬁcacy
and thus to prevent the transition to CRPC. In patients
with locally advanced PCa treated with RT alone, the
5-year disease-free survival rate is 40% (Bolla et al.
2002). Therefore, improving the overall efﬁcacy of RT
could be of signiﬁcant clinical beneﬁt. Several
potential mechanisms lead to RT failure, including
altered proliferative and pro-survival potential, both
of which are frequently observed in PCa.
A frequent genetic lesion that leads to both events
is loss of PTEN function. Sixty percent of PCa
demonstrate loss of heterozygosity at the PTEN locus
(Cairns et al.1 9 9 7 , McMenamin etal.1 9 9 9 ). Decreased
expression of PTEN has been detected in 85% of
primaryPCa tumorscomparedtonormalprostatic tissue
of the same patient (Kremer et al.2 0 0 6 ), and patients
with tumors harboring mutant PTEN have decreased
survival, higher metastatic frequency, and higher
prostate-speciﬁcantigen(PSA)levels,suggestinghigher
AR activity (Pourmand et al.2 0 0 7 ); therefore, PTEN is
one of the most frequently altered genes in human PCa
and is associated with lethal tumor phenotypes. The
PTEN phosphatase serves at the molecular level to
counteract the functions of phosphoinositide 3-kinase,
which promotes proliferation and cell survival, in part
through activation of mTOR (Sansal & Sellers 2004).
Akt serves as an intermediate signaling molecule for
mTOR, which is a serine/threonine kinase that mediates
cell growth, proliferation, survival, protein translation,
and other oncogenic functions.
mTOR activity is often deregulated in Pca (Kremer
et al. 2006), in part due to the prevalence of PTEN
dysfunction. Genomic deletion of PTEN is associated
with both increased Akt activation and AR activity
(Sircar et al. 2009). mTOR mediates proliferation in
PCa cells, at least in part, due to androgen-induced
upregulation of D-type cyclin translation (Gao et al.
2003, Xu et al. 2006b). This event is suggested to,
therefore, promote cell cycle progression. In addition,
mRNA translation events that are dependent on mTOR
are rapidly activated in response to ionizing radiation
(IR), resulting in DNA repair and survival (Braunstein
et al. 2009). As such, the mTOR signaling pathway is
a potential target for enhancing RT efﬁcacy and
improving therapeutic intervention in PCa.
Pharmacological mTOR inhibition has been demon-
strated to block the induction of the proliferative, pro-
survival, and oncogenic functions of mTOR (Hidalgo
& Rowinsky 2000), with remarkable effects in PTEN-
deﬁcient tumors. mTOR inhibitors (e.g. everolimus)
have been approved by the FDA for treatment of renal
cell carcinoma based on a successful phase III clinical
trial (Motzer et al. 2008); thus, mTOR is an established
therapeutic target and mTOR inhibitors appear to be
reasonably well tolerated. At the cellular level, mTOR
inhibitors have been shown to sensitize multiple tumor
types to DNA damage-inducing agents, including IR,
using both in vitro and in vivo models of human disease
(Beuvink et al.2 0 0 5 , Wu et al. 2005, Cao et al. 2006,
Aissat et al. 2008, Morgan et al. 2008, Ekshyyan
et al. 2009, Fung et al. 2009, Matsuzaki et al. 2009,
Murphy et al. 2009, Saunders et al. 2010). Moreover,
mTOR signaling has been implicated as a determinant
of cell survival in response to DNA damage (Shen
et al. 2007).
This study assessed the impact of mTOR inhibition
in clinically relevant models of hormone therapy (HT)-
sensitive PCa and CRPC tumor cells both alone and in
combination with RT. Survival analyses revealed that
mTOR inhibitors sensitized both HT-sensitive PCa
and CRPC cells to IR at clinically attainable doses. The
impact of sequence of mTOR inhibition as a radio-
sensitizer was also assessed, where it was observed that
the radiosensitization events were inﬂuenced by the
scheduling. Strikingly, mTOR inhibitors were most
effective at conferring radiosensitization effects when
administered in the adjuvant setting. Schedule depen-
dence was determined to be due to cell cycle kinetics,
in which neoadjuvant use of mTOR inhibitors limited
entry of the cells into a state of active DNA replication.
On combining these studies, it is demonstrated that
mTOR inhibitors radiosensitize AR-positive PCa
cells dependent on treatment schedule and relative
cell cycle inhibition and provide evidence of a viable
combinatorial treatment strategy.
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Cell culture and reagents
LNCaP, C4-2, and LAPC4 cells were cultured under
standard conditions at 37 8C and 5% CO2 as described
previously (Sharma et al. 2010). Rapa was obtained
from Calbiochem (San Diego, CA, USA) and dissolved
in DMSO. Temsirolimus (Tem) was obtained from
LC Laboratories (Woburn, MA, USA) and dissolved
in ethanol.
Ionizing radiation
A Panatek orthovoltage X-ray irradiator was used to
deliver IR. The irradiator was calibrated daily using
a Victoreen dosimeter.
Cell counting/survival
To monitor cell number over time, indicated cells
were seeded on poly-L-lysine-coated dishes at equal
densities and subjected to treatment/schedules
described. At the time of harvest, cells were trypsinized
and counted using Trypan Blue exclusion and a
hemacytometer. Total cell number was determined
from at least three independent experiments of three
biological replicates.
Cell cycle analysis/bivariate FACS
To monitor bromodeoxyuridine (BrdU) incorpora-
tion/DNA content, LNCaP cells were seeded on poly-
L-lysine-coated dishes at equal densities and subjected
to treatment/schedules described. Two hours prior to
harvest, cells were incubated with BrdU (1:1000,
Amersham Cell Proliferation Labeling Reagent, GE
Healthcare, Buckinghamshire, UK). After labeling,
cellswere trypsinizedandharvested,washedwith PBS,
and then re-suspended in PBS. Cells were then ﬁxed
with cold 100% ethanol, pelleted, then re-suspended
in 2 M HCl, and incubated for 20 min at ambient
temperature. HCl was neutralized with 0.1 M sodium
tetraborate, washed with IFA buffer, followed by a
wash with IFA buffer supplemented with 0.5% Tween
20, then re-suspended in IFA buffer containing 6%
FITC-conjugatedanti-BrdUanti-sera(BD Biosciences,
San Diego, CA, USA), and incubated for 45 min. Cells
were then washed with IFA buffer supplemented with
0.5% Tween 20, stained with propidium iodide
(0.2 g/ml), and subjected to ﬂow cytometry. Samples
were quantiﬁed on a Coulter Epics XL-MCL using XL
SystemIISoftware(BeckmanCoulter,Brea,CA,USA)
and analyzed using FlowJo Software (Tree Star, Inc.,
Ashland,OR,USA).TomonitoronlytheDNAcontent,
LNCaP cells were seeded on poly-L-lysine-coated
dishes at equal densities and subjected to treat-
ment/schedules described. Cells were trypsinized and
harvested, washed with PBS, and then re-suspended in
PBS. Cells were then ﬁxed with cold 100% ethanol,
pelleted, stained with propidium iodide (0.2 g/ml), and
subjected to ﬂow cytometry. Samples were quantiﬁed
on a Coulter Epics XL-MCL using XL System II
Software (Beckman Coulter) and analyzed using
FlowJo Software (Tree Star, Inc.).
Clonogenic cell survival
Exponentially growing cells were trypsinized and
counted using Trypan Blue exclusion. Cells were
dilutedseriallytoappropriateconcentrationsandplated
into 50 ml tissue culture ﬂasks in triplicate for 24 h.
Then, cells were treated with increasing doses of IR (0,
2, 4, 6, and 8 Gy). After 24 h, cells were treated with
Rapa (10 nM), Tem (10 nM), or nothing. After 14 days
of incubation, the colonies were ﬁxed and stained with
4% formaldehyde in PBS containing 0.05% crystal
violet. Colonies containing O50 cells were counted.
Surviving fraction was calculated as (mean colony
counts)/((cells inoculated)!(plating efﬁciency)), in
which plating efﬁciency was deﬁned as (mean colony
counts)/(cells inoculated for un-irradiated controls).
Results
Single-agent mTOR inhibitors or IR limit
HT-sensitive PCa cell growth
mTOR activity has been observed to be increased
in PCa through various mechanisms and upstream
signaling defects. To challenge the consequence
of mTOR inhibition in PCa, HT-sensitive cells were
treated with increasing doses of two pharmacological
inhibitorsof mTOR activity, Rapa and Tem. Ithas been
demonstrated that in this cell type, androgens induce
mTOR signaling that culminates in cell cycle pro-
gression via an increased translation of cyclin D1 (Xu
et al. 2006b), which is part of the molecular machinery
responsible for the G1–S phase transition (Baldin et al.
1993). Consistent with previous reports, mTOR
inhibition resulted in decreased cell number after 72 h
of treatment (Fig. 1A; van der Poel et al. 2003). As
demonstrated, there was no signiﬁcant difference
between either of the mTOR inhibitors tested with
regard to response at any of the doses tested. As IR is
used as deﬁnitive treatment for localized, HT-sensitive
PCa,theeffectofIRonHT-sensitivecellswasassessed.
Theseresultsdemonstrateadose-dependentdecreasein
population cell doubling after exposure to IR (Fig. 1B).
Endocrine-Related Cancer (2012) 19 1–12
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agentmTORinhibitorsandIRaffectHT-sensitivecells.
Additionally, there was no observable difference in the
efﬁcacy of Rapa and Tem in this context.
Combining mTOR inhibition and IR is more
effective than single agent in limiting
HT-sensitive PCa cell number
While IR is a frequently used treatment modality for
locally advanced disease, there is a 10–60% recurrence
rate (Allen et al. 2007), suggesting that means to
improve the efﬁcacy of RT is a signiﬁcant clinical
need. Based on this premise, and the observation that
mTOR signaling is both involved in PCa cell cycle
progression/survival (Gao et al. 2003, Xu et al. 2006b)
and induced by IR (Tirado et al. 2003, Shen et al.
2007), the impact of mTOR inhibition on the response
to IR was determined in HT-sensitive cells. To
determine whether scheduling of the treatment affected
outcome, a strategy was used to test concurrent
(Schedule I), neo-adjuvant (Schedule II), and adjuvant
(Schedule III) mTOR inhibitor administration. The
time from ﬁnal treatment to assessment of outcome
was identical for all schedules tested. Cells were
sensitized to IR when mTOR inhibition was co-admin-
istered (Fig. 2A; compare IR, Rapa, and Tem alone to
RapaCIR and TemCIR). To assess impact on the neo-
adjuvant context, mTOR inhibitors were administered
48 h prior to IR treatment; as shown in Fig. 2B, there
was a signiﬁcant decrease in cell number following this
treatment schedule (compare single agents vs com-
bination). Finally,adjuvant mTOR inhibition conferred
radiosensitization effects (Fig. 2C). Notably, Schedule
III was most effective in limiting cell doubling (w15%
of control) when compared with Schedule I (w20%) or
Schedule II (w23%), suggesting that scheduling of
treatment should be considered in therapeutic design.
The impact of schedule was likely attributed to relative
effects on cell cycle progression and was conserved in
another HT-sensitive PCa cell model (LAPC4; Supple-
mentary Figure 1, see section on supplementary data
given at the end of this article). The LAPC4 model
maintains wild-type PTEN (Whang et al. 1998) and
harbors a mutant p53 allele (van Bokhoven et al.
2003), suggesting that neither PTEN or p53 status
alters the radiosensitization effect of mTOR inhibitors.
Although the contribution of PTEN status to mTOR
inhibitor sensitivity has been documented, data herein
demonstrate that both PTEN-proﬁcient and PTEN-
deﬁcient cells can be radiosensitized by mTOR
inhibition. Of note, the PTEN-proﬁcient cell line
LAPC4 may be intrinsically more radioresistant
compared to the other model systems used. This is
not without precedent, as it as been demonstrated that
this cell line is relatively insensitive to chemotherapy
(Xu et al. 2006a, Qian et al. 2010). However, mTOR
inhibition still renders this cell type more sensitive to
radiation. Taken together, these data demonstrate that
combining mTOR inhibitors with IR is effective in
limiting PCa cell number over time regardless of
scheduling; however, adjuvant use of mTOR inhibitors
may be most efﬁcacious.
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Figure 1 mTOR inhibitors and ionizing radiation (IR) are
sufﬁcient to limit hormone therapy-sensitive prostate cancer
(PCa) cell doubling as single agents (A). LNCaP cells were
treated with indicated doses of rapamycin, temsirolimus, or
vehicle control. 72 h after treatment, cell number was assessed
via Trypan Blue exclusion using a hemacytometer. Cell number
in the vehicle controls was set to ‘1’. Averages of three
independent experiments and S.D. are shown. (B) LNCaP cells
were exposed to the indicated doses of IR. 168 h after
treatment, cell number was assessed via Trypan Blue exclusion
using a hemacytometer. Cell number in un-irradiated controls
was set to ‘1’. Averages of three independent experiments and
S.D. are shown.
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Figure 2 Schedule-speciﬁc radiosensitization of PCa cells by mTOR inhibition (A) Left panel: schematic of Schedule I treatment
strategy (concurrent administration). As depicted, cells were seeded 72 h prior to ﬁnal treatment, mTOR inhibitors, IR, or
combination thereof were administered concurrently (Schedule I; set as time ‘0’), drug was washed out 24 h later, and cell
number was assessed 168 h after treatment. Right panel: LNCaP cells were treated with 10 nM rapamycin (Rapa), 10 nM
temsirolimus (Tem), 2 Gy IR (IR), combination of rapamycin and IR (RapaCIR), combination of temsirolimus and IR (TemCIR),
or vehicle control (untreated). Cell survival in the untreated control was set to 100%; averages of three independent experiments
and S.D. are shown. (B) Left panel: schematic of Schedule II (mTOR inhibitors as neoadjuvant). As depicted, cells were seeded
72 h prior to ﬁnal treatment, administered 10 nM of either mTOR inhibitor, which was washed out of culture media 24 h later,
then 24 h after wash, which at time 0 was exposure to 2 Gy IR, and cell number was assessed 168 h post-IR. Right panel: same
as in (A), but with neoadjuvant mTOR inhibitor administration. (C) Left panel: schematic of Schedule III (mTOR inhibitors as an
adjuvant post-IR). Cells were seeded 72 h prior to ﬁnal treatment, administered 2 Gy IR, and then treated 48 h prior to ﬁnal
treatment (time 0), in this case it was either 10 nM rapamycin or temsirolimus. Right panel: same as in (A) and (B), but with
adjuvant mTOR inhibitor administration. Statistical analysis of the indicated averages was performed using Student’s t-test where
*P!0.05, **P!0.01, and ***P!0.001.
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In addition to being used as a therapy for localized
disease, IR is also used for local recurrence and
metastases, when the cells have frequently become
resistant to HT (CRPC cells). In the presence of
androgens, mTOR inhibition sensitizes CRPC cells to
IR (Fig. 3A). While there was less dependence on
scheduling in this cellular context, Schedule III
(adjuvant) remained the most effective in limiting cell
doubling.ToassesswhethermTORinhibitionsensitizes
CRPC cells to IR in a castrate environment, parallel
studies were performed in steroid-depleted conditions.
mTOR inhibitors retained the capacity to radiosensitize
CRPCcellsinthecastratecondition(Fig.3B),albeittoa
lesser extent than observed inthe presence of androgens
(compared to Fig. 3A). Regardless, Schedule III
remained the most effective, which suggests that there
is a potential cell cycle component involved in the
efﬁcacy of the combination treatment. Since mTOR
inhibitors alone can suppress AR-dependent cyclin D1
accumulation and cell cycle progression, it was
hypothesized that these cytostatic effects underlie the
scheduling effects of mTOR inhibitors.
Relative cell cycle inhibition in combination
treatment is inversely correlated to efﬁcacy of
inhibiting population doubling
To examine the relative cell cycle distribution of cells
in each of the treatment schedules prior to irradiation,
the amount of DNA in cell populations was determined
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Figure 3 mTOR inhibitors sensitize CRPC cells to the effects of irradiation (A) C4-2 cells were treated as in Fig. 2. Top: mTOR
inhibitor administration concurrent with IR (Schedule I). Middle: mTOR inhibitors administered as neoadjuvant to IR (Schedule II).
Bottom: mTOR inhibitors administered as adjuvant to IR (Schedule III). (B) C4-2 cells were cultured in steroid-deprived media and
treated asin (A). Cell survival in the untreated controlis set to 100%, averages of threeindependent experiments and S.D. are shown.
Statistical analysis of the indicated averages was performed using Student’s t-test where *P!0.05, **P!0.01, and ***P!0.001.
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in G1 enrichment in both the concurrent and the
neoadjuvant schedules compared with the adjuvant,
with a concomitant decrease in G2/M enrichment
(Fig. 4A). This observed alteration in cell cycle
distribution resulted in increased cells in a relatively
radioresistant portion of the cell cycle (G1; Yau et al.
1980) and a decrease in the number of cell in a
relatively more radiosensitive portion of the cell cycle
(G2/M; Sinclair & Morton 1966)w h e nm T O R
inhibition was administered either concurrently or as
a neoadjuvant. This same observation held true for
CRPC cells as shown in Supplementary Figure 2A, see
section on supplementary data given at the end of this
article. In order to test the hypothesis that adminis-
tration of mTOR inhibitors prior to the DNA-damaging
insult of IR resulted in cytostatic effects that limited
progression of cells to the radiosensitive cell cycle
window, the relative change in S-phase progression
was assessed for all treatment in the three schedules.
There was signiﬁcant inhibition of BrdU incorporation
in both single-treatment mTOR inhibitor and IR in all
schedules tested (Fig. 4A). The observed inhibition of
S-phase progression was enhanced by combining
mTOR inhibition and IR, but to a lesser extent in
Schedule III (Fig. 4B). Representative PI/BrdU traces
are provided in Supplementary Figure 2B, see section
on supplementary data given at the end of this article.
When these data were compared to the relative impact
on cell number in Fig. 2 (Schedule III being the most
effective in limiting population doubling), there was an
apparent inverse correlation between relative cell cycle
inhibition and inhibition of cell number. Therefore,
while combinatorial treatment in Schedule III was least
effective in limiting BrdU incorporation, it was this
regimen that proved most effective in limiting cell
number over time. To formally assess the impact of
inhibition of cell cycle progression on relative
treatment efﬁcacy, cells were arrested with the DNA
polymerase inhibitor aphidicolin (or not) prior to
combination of mTOR inhibitors and IR (Schedule
III). When the cell cycle was inhibited prior to
administration of the Schedule III regimen, there was
a signiﬁcant alteration of the efﬁcacy of combination
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Figure 4 mTOR inhibitor-induced radiosensitization is a function of relative cell cycle inhibitory effect based on scheduling (A) Left
panels: representative ﬂow cytometry traces for each treatment Schedule that LNCaP cells were subjected to as depicted in Fig. 2
and harvested just prior to when IR would have been administered, ﬁxed, and prepped for FACS analysis of DNA content as
described in the Materials and methods section. Right panels: quantitation of the above. Data represented as relative G1 (left) and
G2/M (right) enrichment averages and S.D. of at least three independent experiments. Schedule III (adjuvant) is set to 1. (B) LNCaP
cells were treated according to the schemata depicted in Fig. 2, then 24 h post treatment, cells were harvested, ﬁxed, and prepped
for FACS analysis of BrdU incorporation and DNA content as described in the Materials and methods section. The data shown
depicts the averages and S.D. of at least three independent experiments analyzing the percent of the cell population that is BrdU
positive compared to untreated control, which is set to 100%. (C) LNCaP cells were either pre-arrested with vehicle control (gray
bars) or aphidicolin (hashed bars) and then subjected to the mTOR inhibitors administered as an adjuvant to IR (Schedule III). Cell
number was assessed 168 h after the last treatment by Trypan Blue exclusion and hemacytometer. Graph represents averages and
S.D. of at least three independent experiments, with survival of untreated cells set to 100%. ***P!0.001.
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demonstrate that limiting cell cycle progression, either
in the context of the scheduling or with another
compound, prior to IR is less effective than using
mTOR inhibitors in an adjuvant context. These data
suggest that the anti-proliferative effect of mTOR
inhibition prior to treatment is likely a detriment to
therapeutic outcome, as the effects of IR may be
greater in cells that are actively cycling, while the anti-
survival effect of these compounds after IR may be of
therapeutic beneﬁt.
mTOR inhibition combined with IR hinders
clonogenic PCa cell survival
To determine whether the observed mTOR inhibitor-
mediated radiosensitization translated in long-term
assays to signiﬁcantly decrease in cell survival/clono-
genicity, the Schedule III regimen was used in a
clonogenic cell survival assay. Both Rapa and Tem
when used in combination with IR signiﬁcantly
decrease clonogenic cell survival in HT-sensitive
(Fig. 5A) and castration-resistant (Fig. 5B) cell models.
These results, in a system that is a validated predictor
of therapeutic response, indicate that adjuvant admin-
istration of mTOR inhibitors decreases PCa cell
survival and replicative capacity.
Discussion
This study identiﬁes mTOR inhibition as a therapeutic
approach that, when combined with IR, suppresses
cancer cell growth. While both IR and the two mTOR
inhibitors tested (Rapa and Tem) showed single-agent
efﬁcacy in limiting PCa cell doubling at clinically
relevant doses (Fig. 1), the data presented in this study
provide evidence that when the combination of IR and
mTOR inhibition is used, there is an additive effect
in limiting both HT-sensitive PCa and CRPC cell
doubling (Fig. 2). This cooperative effect was observed
to be dependent on the scheduling of the treatment
in that treatment of PCa cells with mTOR inhibitor(s)
after IR treatment (adjuvant, Schedule III) resulted in
the most additive effect as determined by both cell
number and BrdU incorporation (Figs 2 and 4).
Further, this observation was supported by the ﬁnding
that arresting the cell cycle prior to administration of
the most effective schedule reduced the efﬁcacy of this
treatment regimen (Fig. 4B). Finally, using clonogenic
cell survival modeling, which is a predictor of in vivo
efﬁcacy (Wilson et al. 1984, Hirabayashi et al. 1987,
Yung 1989), it was observed that adjuvant adminis-
tration of either of the mTOR inhibitors tested resulted
in decreased replicative capacity of both HT-sensitive
PCa and CRPC cells (Fig. 5). Only the schedule that
proved to be most effective with respect to radio-
sensitization was utilized in the clonogenic assay. This
was to ensure that any observed effects on sensitivity
were not due to relative baseline plating efﬁciency to
prior mTOR inhibitor administration. Together, these
studies demonstrate that mTOR inhibition can radio-
sensitizePCacells,andschedulingofthetreatmentalters
the ultimate outcome as determined by both monitoring
population doubling and clonogenic cell survival.
Despite the approved use of mTOR inhibitors for the
treatment of renal clear cell carcinoma (RCC), there
are few data regarding the impact of mTOR as a
therapeutic target in PCa. However, a recent pharma-
codynamic study (Armstrong et al. 2010) demonstrated
that an mTOR inhibitor (Rapa) could be administered to
men with localized PCa, attaining high intra-prostatic
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Figure 5 Clonogenic cell survival of both hormone therapy-
sensitive and CRPC cells is reduced with mTOR inhibition
following IR (A) LNCaP cells were serially diluted to appropriate
concentrations and seeded in 50 ml tissue culture ﬂasks. 24 h
later, cells were exposed to indicated doses of IR. After 24 h,
cells were treated with 10 nM rapamycin, 10 nM temsirolimus,
or vehicle control. Cells were incubated for 14 days, ﬁxed,
stained with crystal violet, and colonies were counted. Colonies
containing O50 cells were considered in the analysis. The data
are represented on a semi-log scale, where the x-axis
represents the dose of IR and the y-axis represents the mean
surviving fraction and S.D. (B) C4-2 cells were seeded, treated,
processed, counted, and analyzed as in (a).
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and effectively limiting mTOR signaling as determined
by S6 kinase phosphorylation, which is a downstream
effector of mTOR activity involved in protein
translation. While there was little signiﬁcant biological
effect in these tumors with regard to cellular outcomes
(as determined by the assessment of proliferative and
apoptotic indices), this may have been a result of the
short course of treatment (14 days). Nonetheless, these
clinical data demonstrate the feasibility of targeting
mTOR in PCa cells, thus revealing a potentially fruitful
platform for combination therapy. There are currently
a number of clinical trials at various stages, some
using mTOR inhibitors as single agents and others
in combination with agents such as docetaxel or
AR-directed strategies (as reviewed in Morgan et al.
(2009)); however, none of these trials are investigating
the combinatorial use of IR and mTOR inhibition
in PCa. While this study indicates some modest impact
of mTOR inhibitors as single agents, the most
signiﬁcant anti-tumor activity was observed in com-
bination with IR. Therefore, the data presented herein
demonstrating the radiosensitization of both HT-sensi-
tive and CRPC cells in the clonogenic cell survival
assay emphasize the importance of considering
treatment schedule and provide the basis for clinical
investigations. These data present a substantive
advance, as there are no clinical agents currently
approved, which confer sensitization to RT aside from
androgen deprivation therapy (ADT). Of note, in CRPC
cells cultured in conditions mimicking ADT, mTOR
inhibition served as a radiosensitizer as well.
A critical ﬁnding herein was that the efﬁcacy of
mTOR inhibitors as a means to radiosensitize was
signiﬁcantly inﬂuenced by treatment schedule in both
HT-sensitive PCa and CRPC cells. The evidence
shown suggests that the observed schedule dependence
can be attributed to the impact of mTOR inhibitors
on cell cycle progression. The G1 arrest induced by
mTOR inhibitors prior to IR protected against
radiation-induced cellular outcomes, whereas mTOR
inhibitors in the adjuvant setting resulted in a more
robust decrease in cell doubling. Interestingly, the
effect of mTOR inhibitors was not inﬂuenced by
PTEN status, as both PTEN-proﬁcient (LAPC4) and
PTEN-deﬁcient (LNCaP) cells exhibited similar
response to schedule-dependent combination therapy.
Moreover, the impact of mTOR inhibition on radio-
sensitization was independent of p53 status as, in
contrast to LNCaP cells, the LAPC4 model system
lacks functional p53 (van Bokhoven et al. 2003).
Schedule-dependent sensitization to DNA damaging
therapies by mTOR inhibition is not without precedent.
It has been demonstrated that co-treatment of
doxorubicin with an mTOR inhibitor was synergistic
in T-cell lymphoma in vitro (Huang et al. 2010), as was
adjuvant administration of mTOR inhibitor, compared
to neo-adjuvant mTOR inhibition with these agents,
which resulted in no synergistic effect on cellular
outcomes. Additionally, it has been demonstrated
that Tem administered to HT-sensitive PCa cells after
docetaxel was more effective in limiting clonogenic
cell survival, compared with concomitant treatment
(Fung et al. 2009). These collective observations
underscore the importance of assessing the impact of
sequencing when combining mTOR inhibitors with
genotoxic agents, especially with regard to the relative
impact of these agents to alter cell cycle inhibition.
As demonstrated herein, administration of mTOR
inhibitors prior to radiation results in larger proportions
of the cell populations being in relatively radioresistant
portions of the cell cycle (G1) and fewer cells in
radiosensitive portions (S and G2/M).
As demonstrated herein, clinically relevant doses of
both Rapa and Tem exhibit single-agent cytostatic
and cytotoxic effects in PCa cells and conferred
schedule-dependent radiosensitization. The underlying
mechanism(s) by which adjuvant administration of
mTOR inhibition sensitizes cells to RT is the focus of
ongoing investigation. Recently, it was demonstrated
that mTOR is directly involved in the repair of DNA
damage with respect to double-strand breaks, which
occur frequently in cells exposed to IR (Chen et al.
2010), and these effects could therefore contribute
to the radiosensitization observed in this study.
Consonantly, it has been demonstrated that mTOR
inhibition confers radiosensitization phenotypes in
multiple tumor types (Ekshyyan et al. 2009, Nagata
et al. 2010, Saunders et al. 2010), and that mTOR
inhibition radiosensitizes soft tissue sarcoma and
tumor vasculature (Murphy et al. 2009), which could
have a similar impact on the response to RT. mTOR
inhibitors also show cooperative effects with RT-
independent DNA damaging agents, including doxo-
rubicin (in T-cell lymphoma (Huang et al. 2010)),
5-ﬂuorouracil and/or docetaxel (in gastric cancer
(Matsuzaki et al. 2009)), carboplatin and paclitaxel
(in head and neck cancer (Aissat et al. 2008)), and
cisplatin (in hepatocellular carcinoma (Aissat et al.
2008)). In PCa cells, limited evidence suggests that
mTOR inhibition can confer sensitization to doxor-
ubicin (Grunwald et al. 2002), and combining mTOR
inhibitors with docetaxel has been shown to be
effective in limiting PCa cell growth in vitro and
in vivo in a schedule-dependent manner (Fung et al.
2009). While mTOR inhibitors have been shown to
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both in vitro and in vivo (Wu et al. 2005, Cao et al.
2006), the relevance of these models to the majority of
human tumors, which retain AR, remains uncertain.
One study has demonstrated that mTOR inhibition and
docetaxel administration is an effective combination in
an intra-tibial AR-positive model of PCa (Morgan
et al. 2008), while the other has shown that combining
mTOR inhibition and AR antagonistic therapy results
in PCa cell apoptosis and delayed progression to
castration resistance (Schayowitz et al. 2010). As such,
mTOR inhibitors appear to harbor the capacity to
improve responses to RT and selected DNA damage-
inducing therapeutics, as well as AR-directed
strategies.
In summary, the studies presented herein demon-
strate that mTOR inhibitors exhibit schedule-depen-
dent effects on the RT response in PCa cells and confer
signiﬁcant radiosensitization effects when used in the
adjuvant setting. Remarkably, the effects of mTOR
inhibition as a means to achieve radiosensitization was
conserved in both the HT-sensitive PCa and the CRPC
settings, thus indicating that mTOR inhibitors may
be an effective means to improve response to DNA
damage-inducing therapeutic regimens in advanced
disease. Combining these data herein provide the
foundation for clinical investigation and illuminate
new means by which PCa treatment may be improved.
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